Complix NV, a Belgium-based developer of “alphabodies” for autoimmune and infectious diseases, has raised €5 million in Series A funding. Backers include Vesalius Biocapital, LRM and CRP Santé.
Complix NV, a recently founded biopharmaceutical company, announced the successful closing of its Series A financing round, raising € 5 million (~US$ 6.25 million) from a syndicate of leading life sciences investors.
The transaction was co-led by Vesalius Biocapital (Luxembourg) and LRM (Belgium), with CRP Santé (Luxembourg), existing investors and management also participating. Complix is focused on the discovery and development of next generation drugs based on “Alphabodies”, a novel class of biopharmaceuticals with superior therapeutic potential. Complix also announced the creation of a fully-owned subsidiary in Luxembourg to develop novel Alphabody™ based therapies against viral diseases in a strategic collaboration with CRP-Santé (Centre de Recherche Public de la Santé).